8-K: Biodesix Exceeds Q4 Revenue, Achieves First-Ever Positive Adjusted EBITDA

Biodesix, Inc. announced strong fourth quarter and fiscal year 2025 results, surpassing revenue guidance and achieving its first quarter of positive Adjusted EBITDA.

Summary

• Total revenue for Q4 2025 reached $28.8 million, a 41% increase over Q4 2024, exceeding the high end of guidance.
• Fiscal year 2025 total revenue was $88.5 million, representing 24% growth compared to fiscal year 2024.
• Diagnostic Test revenue grew 46% in Q4 2025 to $25.1 million and 22% for FY 2025 to $79.2 million.
• Test volumes increased by 23% in Q4 2025 to 18,000 and 15% for FY 2025 to 62,600.
• Gross margin expanded to 83% in Q4 2025 (up 400bps) and 81% for FY 2025 (up 300bps).
• Net loss improved by 52% in Q4 2025 to $4.0 million and by 18% for FY 2025 to $35.3 million.
• Achieved first-ever Adjusted EBITDA positivity in Q4 2025, reaching $0.5 million, a 113% improvement from Q4 2024.
• Fiscal year 2025 Adjusted EBITDA loss improved by 21% to $17.5 million.
• Pro forma cash and cash equivalents stood at $33.7 million, including $14.7 million in ATM proceeds raised subsequent to year-end.
• The Senior Secured Term Loan with Perceptive Advisors was amended to extend the maturity date and interest-only period to November 2028.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, driven by exceeding revenue guidance, achieving the first-ever positive Adjusted EBITDA, and demonstrating significant improvements in gross margin and net loss, alongside a positive outlook for 2026.

Positives

• Exceeded the high end of revenue guidance for Q4 2025, delivering $28.8 million, a 41% growth.
• Achieved first-ever Adjusted EBITDA positivity in Q4 2025 with $0.5 million, demonstrating strong operating leverage.
• Gross margin expanded significantly to 83% in Q4 2025 and 81% for the full fiscal year 2025.
• Net loss improved substantially by 52% in Q4 2025 and 18% for the full fiscal year 2025.
• Diagnostic Test revenue and test volumes showed robust growth, driven by increased payer coverage and improved revenue cycle management.
• Development Services revenue increased by 41% for the full fiscal year 2025, reflecting successful contract delivery and new agreements.
• Strengthened the balance sheet and increased financial flexibility by extending the Senior Secured Term Loan maturity and interest-only period to November 2028.

Negatives

• Despite significant improvements, the company still reported a net loss of $35.3 million for the full fiscal year 2025.
• Adjusted EBITDA for the full fiscal year 2025 remained a loss of $17.5 million, although improved.

Risks

• Forward-looking statements involve substantial risks and uncertainties, and actual results could differ materially from projections.
• Risks include those related to revenues, profitability, overall business strategy, timing and assumptions regarding revenue collection, availability of funds and future capital.
• Potential impact of new clinical data, reimbursement coverage, research partnerships, enhanced U.S. tariffs, import/export restrictions, or other trade barriers could affect financial performance.

Future Outlook

Biodesix anticipates generating between $106-112 million in total revenue for 2026, with the mid-point reflecting 23% growth over 2025. The company expects continued improvement towards sustained Adjusted EBITDA positivity, driven by increased sales force productivity, improved average revenue per test, additional clinical data for Nodify Lung tests, growth in the Development Services pipeline, and demonstrated operating leverage. Gross margin is expected to be maintained at approximately 80% in FY 2026.

Management Comments

• "Biodesix delivered exceptional results in the fourth quarter, with revenue of $28.8 million and 83% gross margin."
• "We exceeded the high end of our revenue guidance by delivering 41% growth, and for the first time ever, achieved Adjusted EBITDA positivity in the quarter demonstrating the strength of our operating leverage and gross margins, which have become a hallmark of Biodesix performance."
• "In 2025, we accelerated the growth of our lung-focused commercial strategy, expanded our pipeline, announced new partnerships, grew our development services offering, and presented clinical data on our on-market and pipeline products."

Industry Context

StockSavvy.ai notes that Biodesix's strong revenue growth and achievement of positive Adjusted EBITDA in Q4 2025 indicate a positive trajectory within the diagnostic solutions sector, particularly in lung disease. The focus on expanding commercial strategy, pipeline, and development services aligns with broader industry trends towards specialized diagnostics and strategic partnerships to drive growth and market penetration. The company's ability to improve gross margins and operating leverage suggests efficient execution in a competitive market.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct industry standard comparison.

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, exceeding guidance, and a positive outlook, potentially leading to increased share value.
• Employees: Positive impact due to an expanded sales team and expected continued operating leverage, suggesting job stability and growth opportunities.
• Customers (Healthcare Providers/Patients): Continued benefit from Biodesix's diagnostic solutions (Nodify Lung, IQLung) with ongoing clinical data and improved payer coverage.
• Creditors (Perceptive Advisors): The extension of the Senior Secured Term Loan maturity provides stability and a longer repayment horizon.

Next Steps

• Continue increasing productivity across the expanded sales organization.
• Drive adoption of Nodify Lung tests from healthcare providers and payers through additional clinical data.
• Increase the Development Services pipeline.
• Maintain focus on operating leverage to achieve sustained Adjusted EBITDA positivity.
• Host a conference call and webcast on February 26, 2026, at 4:30 p.m. ET to discuss results.

Key Dates

Recommendation

The filing demonstrates exceptional financial performance, significantly exceeding revenue guidance and achieving a pivotal milestone with its first-ever positive Adjusted EBITDA. The substantial improvements in gross margin and net loss, coupled with a strong revenue growth outlook for 2026 and enhanced financial flexibility from the loan amendment and capital raise, indicate a robust operational turnaround and strong future potential. These results suggest the company is on a clear path to sustained profitability, making it an attractive investment.

Keywords

Biodesix, BDSX, Diagnostic Solutions, Lung Disease, Nodify Lung, IQLung, Q4 2025 Results, Fiscal Year 2025, Revenue Growth, Adjusted EBITDA, Gross Margin, SEC Filing, Financial Performance, Biopharmaceutical, Life Sciences